Eligible patients were randomly assigned ( @:@ ) using a central patient screening and randomisation system to daily everolimus ( @ mg/day ) plus weekly trastuzumab ( @ mg/kg ) and vinorelbine ( @ mg/m ( @ ) ) or to placebo plus trastuzumab plus vinorelbine , in @-week cycles , stratified by previous lapatinib use .